Digital Health Market Insights - Winter 2025

• After a quarter-over-quarter decline in Q3’25, global digital health equity funding rebounded in Q4’25, totaling $5.4B, representing a 12.5% quarter-over-quarter increase.
• The funding environment continues to concentrate around scaled, later-stage platforms, with median pre-money valuations increasing to $31M in 2025 (from $26.5M in 2024) and average global digital health equity deal size rising to $20.3M (from $15.8M in 2024), as investors prioritize companies demonstrating clear product-market fit and revenue traction. This trend has been particularly pronounced among AI-enabled healthcare platforms, which continue to command valuation premiums and attract significant venture growth capital.
• AI-enabled healthcare platforms remain the primary driver of investment activity, with capital increasingly directed toward clinical documentation, clinical decision support, provider workflow automation, and administrative efficiency solutions. Recent financings highlight this trend, including Ōura’s $907.7M Series E at an $11B valuation, OpenEvidence’s $200M raise at a $6B valuation, and Hippocratic AI’s $126M round at a $3.5B valuation, reflecting strong investor conviction in AI-native healthcare infrastructure and workflow platforms.
• M&A activity moderated in Q4’25, with announced exits declining from 65 in Q3’25 to 36 in Q4’25. The largest transaction during the quarter was Thermo Fisher Scientific’s $8.88B acquisition of Clario, a provider of endpoint data solutions supporting clinical trials.
• Overall, investors continue to view digital health as a structurally attractive market, with capital flowing toward segments where AI-driven automation can meaningfully reduce clinical and administrative burdens.

Sources: CB Insights; PitchBook

The longevity market encompasses therapeutics, diagnostics, digital platforms, and consumer solutions aimed at extending healthspan and preventing age-related disease. The market is driven by aging demographics, rising chronic disease burden, and advances in AI.

• The traditional boundary between health care and beauty is narrowing as consumers increasingly demand scientifically validated products. Beauty and aesthetics companies are moving beyond purely cosmetic positioning and investing in biologically grounded claims to back new innovations.
• Global aging trends are accelerating. Adults aged 60 and older now represent a significant share of the global population and are projected to exceed 2 billion people by 2050. This demographic shift is pressuring health systems, pension structures, and labor markets. In response, governments are increasingly framing longevity around health span.
• Companies such as Function Health are gaining traction by positioning longevity around proactive diagnostics and continuous health monitoring. These platforms combine advanced lab testing, biomarker tracking, and personalized insights to identify risk before clinical disease manifests.

Sources: Deloitte; Mordor Intelligence; WHO; Founder Forum Group; HTF Market Intelligence

The global longevity tech market was valued at $3.4B in 2024 and is projected to grow at a CAGR of 10.4%, reaching $7.5B by 2032